Moreover, recently, Tazi Y et al. proposed a distinctive genetic category of AML mainly defined by the presence of WT1 mutations in the absence of other genetic subtype-defining events associated with poor outcome, comparable to that of other adverse-risk features, when associated with FLT3-ITD co-mutation [7]. This evidence concerns the gene WT1 and acute myeloid leukemia.